Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Enanta Pharmaceuticals

07/08/2026 23:41

Enanta Pharmaceuticals Inc ENTA.OQ ENTA.O is expected to  show a fall in quarterly revenue when it reports  results on August 10 for the period ending June 30 2026
The Watertown Massachusetts-based  company is expected to report a 8.3% decrease in revenue to $16.796 million from $18.31 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data. (Majority SAL is on Total Revenue basis)
​LSEG's mean analyst estimate for Enanta Pharmaceuticals Inc is for a loss of 51 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 45.2% above its last closing price of $13.77
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.46
-0.49
-0.45
Beat
7.8
Dec. 31 2026
-0.91
-0.81
-0.42
Beat
48
Sep. 30 2025
-1.03
-1.02
-0.87
Beat
14.8​
Jun. 30 2025
-1.20
-1.28
-0.85
Beat
33.4
​​Mar. 31 2025
-1.12
-1.14
-1.06
Beat
6.7
Dec. 31 2024
-1.36
-1.35
-1.05
Beat
22.4​
Sep. 30 2024
-1.10
-1.16
-1.36
Missed
-17.2
Jun. 30 2024
-1.40
-1.45
-1.07
Beat
26.2
This summary was machine generated August 7 at 22:41 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)